Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
Information source: University of Nebraska
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Renal Insufficiency
Intervention: Zoledronic Acid (Drug); calcium and Vitamin D (Drug); Alendronate (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: University of Nebraska Official(s) and/or principal investigator(s): Lynn Mack-Shipman, MD, Principal Investigator, Affiliation: University of Nebraska
Summary
The study is designed to look at the effect of different bone treatment plans on bone loss
after kidney or kidney/pancreas transplant.
Clinical Details
Official title: Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Percent change in Posterior Anterior (PA) spine bone density from baseline to 24 months post transplant
Secondary outcome: Percent change in PA spine bone density from baseline to 12 months and percent change in total hip bone density from baseline to 24 monthsPatient compliance will be quantified in the alendronate and placebo groups as the percentage of pills distributed that were taken. The occurence of side effects will be summarized using descriptive statistics and compared among the treatment groups.
Detailed description:
The aims are to determine baseline bone mineral density (BMD) in kidney and kidney/pancreas
transplant patients who will be randomized to weekly alendronate, annual zoledronic acid
infusions or placebo (calcium with Vitamin D). These patients will be followed for two
years with annual bone density testing as well as biochemical markers. A secondary aim is
to evaluate compliance and tolerability of taking annual intravenous zoledronic acid versus
weekly alendronate in the transplant recipient.
Eligibility
Minimum age: 19 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Transplant patients who have had a kidney or kidney/pancreas transplant in the last
150 days with adequate kidney function as defined by a calculated creatine clearance
of 35ml/min or more and serum creatinine less than 3. 0
Exclusion Criteria:
- Dual X-ray Absorptiometry (DXA) T-score at the spine or hip of -3 or lower
- History of more than one vertebral or non-vertebral fracture in the past two years
- Abnormalities of the esophagus which delay esophageal emptying
- Inability to stay upright for 30 minutes
- Pregnant, nursing women or women not using an effective form of birth control
- Hypocalcemia
- Hypercalcemia
- Calculated creatinine clearance of <35 ml/min or serum creatinine > 3. 0
- Patients already treated with bisphosphonates within the past one year
- Patients unable to undergo DXA
- Patients with cancer
Locations and Contacts
University of Nebraska Medical Center, Omaha, Nebraska 68198, United States
Additional Information
Starting date: December 2003
Last updated: January 2, 2014
|